Autologous T cells are engineered to express a CD19-specific chimeric antigen receptor that recognizes CD19 on B-lineage cells (including plasmablasts). Upon antigen engagement, CAR T cells activate and mediate cytotoxic killing of CD19+ cells, depleting pathogenic B-cell populations to reduce autoantibody production and reset humoral immunity in autoimmune disease.